Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial
Ross A. Soo, Eng Huat Tan, Hidetoshi Hayashi, Takashi Seto, Chia‐Chi Lin, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Geoffrey Liu, Antonello Abbattista, Jean-François Martini, Chew Hooi Wong, Francesca Toffalorio, Benjamin Solomon
Topics & Concepts
MedicineInternal medicineCrizotinibLung cancerHazard ratioConfidence intervalClinical endpointOncologyPopulationALK inhibitorAdverse effectCancerGastroenterologyClinical trialEnvironmental healthMalignant pleural effusionLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies